跳至主要内容
临床试验/ACTRN12619001347156
ACTRN12619001347156招募中1 期

Orkambi in Patients with Cystic Fibrosis and Severe Liver Disease

Dr Adeline Lim0 个研究点目标入组 30 人开始时间: 2019年10月1日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
2 Years 至 18 Years(—)
性别
All

入选标准

  • 1. Children between 6 years old and 18 years of age homozygous for Phe508del-CFTR
  • 2. Severe cystic fibrosis related liver disease
  • 1. Children between 2 years old and 18 years of age homozygous for Phe508del-CFTR
  • 2. Severe cystic fibrosis related liver disease
  • Patients without severe cystic fibrosis related liver disease
  • 1. Children between 2 years old and 18 years of age homozygous for Phe508del-CFTR
  • 2. On full dose Orkambi for at least two weeks prior to enrolment to the study

排除标准

  • Cystic fibrosis without severe liver disease
  • Exclusion criteria - presence of cirrhosis and portal hypertension
  • These patients must already be receiving full dose Orkambi for at least two weeks prior to enrolment to this group.

研究者

发起方
Dr Adeline Lim

相似试验